L. Zhang

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 468 citations

Medicine, Oncology, Pharmacology +14

Recent advances in short peptide self-assembly: from rational design to novel applications

Xuzhi Hu, Mingrui Liao, Haoning Gong et al. · Current Opinion in Colloid & Interface Science · 2019 · 154 citations

Life Sciences, Biochemistry, Medicinal Chemistry +14

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

Pier Luigi Zinzani, Julie M. Vose, M. S. Czuczman et al. · Annals of Oncology · 2013 · 120 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 120 citations · Full text

Medicine, Oncology, Pharmacology +14

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

L. Zhang, Shun Lü, J. Feng et al. · Annals of Oncology · 2017 · 112 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17